Updated

Updated · Financial Times · Jun 16

Jardine Matheson Buys I-MED for $2.4 Billion as It Pivots Toward Developed Asia-Pacific

Updated

Updated · Financial Times · Jun 16

Jardine Matheson Buys I-MED for $2.4 Billion as It Pivots Toward Developed Asia-Pacific

Q: After its $2.4B healthcare bet, which industry will Jardine's recycled capital target next in its strategic overhaul?

After the $2.4 billion I-MED acquisition in healthcare, Jardine Matheson’s recycled capital is expected to target **wealth and infrastructure** next, with a broader emphasis on **green and sustainable infrastructure** tied to the energy transition. That is the clearest read from the company’s investor-day strategy. Jardines said it wants greater exposure to sectors better aligned with Asia-Pacific growth, explicitly citing **healthcare, wealth and infrastructure**. Since healthcare has already been addressed through I-MED, the next logical targets are wealth and infrastructure. The wider strategic material also shows what “infrastructure” is likely to mean in practice: investments linked to **green energy, EV charging, battery supply chains and other sustainable infrastructure** opportunities, particularly in developed Asia-Pacific markets such as Australia and selectively across Southeast Asia. This fits Lincoln Pan’s overhaul of Jardines into a more active capital allocator, using at least $4 billion of recycled capital by 2030 to buy scaled businesses capable of generating returns above its 11% hurdle. While the exact next deal has not been named, the company’s stated direction points most clearly to **wealth and infrastructure, especially green infrastructure-related assets**.

2 articles · Updated · Financial Times · Jun 16

$2.4 billion I-MED deal marks Jardine Matheson’s clearest shift yet toward developed Asia-Pacific assets, with the group saying it wants to offset a portfolio heavily concentrated in Indonesia.
Lincoln Pan said Jardines plans about three acquisitions of similar size over the next four to five years, targeting at least 11% returns on new investments and reviewing assets yielding under 7%.
The strategy keeps Astra at the center of the group, but seeks lower-capital businesses after what Pan called a tough Indonesian operating environment, where an Astra unit briefly lost mining rights before they were restored.
By 2030, Jardines aims to recycle at least $4 billion of capital and deliver 9% annual total shareholder return, underscoring its shift from owner-operator to investment manager.
Investors have largely backed the overhaul after a 38% share-price rise over 12 months, though some question whether combining Indonesian industry, Australian healthcare and Hong Kong property creates an awkward mix.

Sources

Center100%

Financial Times1d ago

Jardine Matheson Pivots to Developed Markets with $2.4bn I-MED Acquisition

Citeline1d ago

Medtech Deals

After its $2.4B healthcare bet, which industry will Jardine's recycled capital target next in its strategic overhaul?

Is Jardine's pivot from Indonesia a masterstroke or a massive gamble on slower-growing, safer markets?

Can a 194-year-old giant truly mimic a private equity firm without sacrificing its long-term operational strengths?

Jardine Matheson Acquires I-MED Radiology for A$3.4 Billion: Market Impact, AI Ambitions, and Future Growth

Overview

Jardine Matheson’s acquisition of I-MED Radiology marks a major move into the healthcare sector, announced on May 25, 2026. I-MED operates 215 clinics across Australia and New Zealand, performing over 7 million procedures annually and leading in teleradiology services. Its strong market position, broad service range, and investment in AI through Harrison.ai made it an attractive, future-proof asset. The deal is expected to boost Jardine Matheson’s long-term growth, following its strategy of investing in market-leading businesses. Permira’s sale of I-MED reflects a successful private equity cycle, highlighting I-MED’s transformation and market leadership.

...